Matthias Cheung, PhD, Discusses Current Federal Legislation and Ongoing Policies Regarding Orphan Drugs and Rare Disease
Matthias Cheung, PhD, FCSHP, FASHP, a principal at Advanced Rx Consulting, LLC, and an adjunct professor of pharmacy practice at the University of the Pacific, Thomas J. Long School of Pharmacy and Health Services, discusses the circumstances and factors that catalyzed the passage of current legislation and regulatory policies for orphan drugs, rare diseases, and ultra-rare diseases.
This video was taken at the Academy of Managed Care Pharmacy's 25th Annual Meeting & Expo in San Diego, CA, on April 5, 2013.
Results presented today at the American College of Rheumatology in Boston show that a 12-biomarker test did a better job of predicting radiographic progression in patients with RA. The study demonstrates how biomarkers are becoming important in managed care outside of cancer treatment.
The study, published in the Journal of Thoracic Oncology, identified race, insurance status, and the treatment center as variables that influenced treatment received by individuals with early-stage lung cancer.
In a paper published in the Journal of Clinical Oncology, medical oncologists have delineated their recommendations to improve cancer care and provide better access to quality care for those patients with financial issues and on Medicaid.